CTEC Global X CleanTech ETF

HAYWARD, Calif., Sept. 14 /PRNewswire-FirstCall/ -- Cholestech Corporation (NASDAQ:CTEC), a leading manufacturer of point of care testing devices, announced it has shipped the first orders for the Cholestech LDX(R) hs-CRP diagnostic test. The new hs-CRP test offers fast, accurate detection of low grade inflammation from a single drop of blood, and is now available in the primary care setting. C-reactive protein (CRP) is a systemic marker of inflammation. The hs-CRP test is used to detect low level increases in CRP in apparently healthy individuals. These increases are due to more subtle forms of inflammation, such as inflammation in the blood vessels, and cannot be detected using conventional CRP assays. "Physicians now recognize that inflammation plays a major role in cardiovascular disease and that measurement of hs-CRP along with cholesterol provides an improved method to identify individuals at high risk for both heart attack and stroke," said Dr. Paul Ridker, a cardiologist at the Brigham and Women's Hospital in Boston and a leading researcher in CRP and vascular disease prevention. An expanding body of research indicates that increased hs-CRP levels are associated with the development of atherosclerosis, independent of cholesterol. Considered similar to how arthritis is an inflammatory disorder of the bones and joints, atherosclerosis is now considered in many ways an inflammatory disorder of the blood vessels. According to the Centers for Disease Control and Prevention and the American Heart Association, measurement of hs-CRP may help direct further evaluation and therapy in the primary prevention of cardiovascular disease. However, increases in CRP are nonspecific, and should be interpreted in the context of a complete clinical evaluation. Healthy individuals with elevated values should have the test repeated in order to help rule out a recent response to undetected infection or tissue injury. The Cholestech LDX(R) System supports the measurement of hs-CRP, cholesterol and other lipid tests, glucose and liver enzymes, ALT and AST, at the point-of-care by using a simple finger-stick. Point-of-care testing enables physicians to quickly identify patients with risk factors for heart disease and allows them to offer treatment or counseling in the same office visit. Generating comprehensive, lab accurate results in minutes, the LDX System enables physicians to focus on getting patients on the right treatment sooner and making sure they stay on the right therapeutic mix, rather than chasing down lab results. "Based on the work of Dr. Ridker and his colleagues, the role of hs-CRP in the detection of subtle changes in inflammation and its impact on overall health has increased significantly. We are proud to expand the utility of the LDX System, already a leading cholesterol monitoring tool, to include this important prognostic test," said Warren E. Pinckert II, president and CEO of Cholestech. About Cholestech Cholestech is committed to enabling people to lead longer, healthier and more active lives. Cholestech provides easy to use, accessible diagnostic tools and information to health care practitioners in over 35 countries around the world. Cholestech offers efficient and economic diagnostic testing for cholesterol and related lipids, hs-CRP, blood glucose and A1C, and liver function at the point of care. Health care providers can use the Cholestech LDX and GDX(TM) Systems to initiate and monitor the progress of patient therapy. By providing effective disease management solutions, Cholestech's goal is to be a leading provider of diagnostic tools and information for immediate risk assessment and therapeutic monitoring of heart disease and diabetes. NOTE: Cholestech LDX(R) is a registered trademark and Cholestech GDX(TM) is a trademark of Cholestech Corporation. All other trademarks mentioned in this document are the property of their respective owners. For more information about Cholestech and its products, visit us on the web at http://www.cholestech.com/. DATASOURCE: Cholestech Corporation CONTACT: Warren E. Pinckert II, President and Chief Executive Officer of Cholestech Corporation, +1-510-732-7200, or ; or Press, Chris K. Joseph of ckj Communications, +1-510-339-2293, or ; or Investors, Jim Byers of Financial Dynamics, +1-415-439-4504, or , both for Cholestech Corporation Web site: http://www.cholestech.com/

Copyright